UroGen Pharma (URGN) Debt to Equity: 2022-2025
Historic Debt to Equity for UroGen Pharma (URGN) over the last 4 years, with Sep 2025 value amounting to -$1.06.
- UroGen Pharma's Debt to Equity fell 122.18% to -$1.06 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.06, marking a year-over-year decrease of 122.18%. This contributed to the annual value of -$13.83 for FY2024, which is 815.06% down from last year.
- Latest data reveals that UroGen Pharma reported Debt to Equity of -$1.06 as of Q3 2025, which was up 19.35% from -$1.31 recorded in Q2 2025.
- In the past 5 years, UroGen Pharma's Debt to Equity ranged from a high of $4.77 in Q3 2024 and a low of -$13.83 during Q4 2024.
- For the 3-year period, UroGen Pharma's Debt to Equity averaged around -$1.70, with its median value being -$1.31 (2025).
- Data for UroGen Pharma's Debt to Equity shows a peak YoY increase of 554.42% (in 2024) and a maximum YoY decrease of 815.06% (in 2024) over the last 5 years.
- Over the past 4 years, UroGen Pharma's Debt to Equity (Quarterly) stood at -$1.09 in 2022, then crashed by 38.46% to -$1.51 in 2023, then crashed by 815.06% to -$13.83 in 2024, then plummeted by 122.18% to -$1.06 in 2025.
- Its Debt to Equity was -$1.06 in Q3 2025, compared to -$1.31 in Q2 2025 and -$2.63 in Q1 2025.